Information Provided By:
Fly News Breaks for September 24, 2019
Sep 24, 2019 | 08:36 EDT
Jefferies analyst Chris Howerton initiated coverage of Corcept Therapeutics with a Buy rating and $20 price target. The analyst sees the generic Korlym challenges as "winnable" and he believes relacorilant will maintain and potentiality grow the company's Cushing's syndrome market share. In addition, Corcept's oncology programs add modest value due to their early stage, and its other pipeline indications are call options, Howerton tells investors in a research note.
News For CORT From the Last 2 Days
There are no results for your query CORT